Solventum (NYSE:SOLV) Stock Price Expected to Rise, Morgan Stanley Analyst Says

Solventum (NYSE:SOLV) had its price target raised by analysts at Morgan Stanley from $73.00 to $80.00 in a research report issued on Wednesday,Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Morgan Stanley’s price objective would suggest a potential upside of 5.70% from the stock’s current price.

A number of other brokerages also recently weighed in on SOLV. Bank of America lifted their target price on Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a report on Wednesday, February 26th. Mizuho raised their price target on shares of Solventum from $70.00 to $82.00 and gave the stock a “neutral” rating in a report on Monday. Wells Fargo & Company lifted their price target on shares of Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a research note on Friday, February 28th. Piper Sandler increased their price objective on shares of Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a research report on Friday, February 28th. Finally, The Goldman Sachs Group boosted their target price on Solventum from $63.00 to $71.00 and gave the company a “sell” rating in a research report on Monday. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and one has issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $79.86.

Solventum Price Performance

Shares of NYSE SOLV opened at $75.69 on Wednesday. The company has a market capitalization of $13.08 billion and a PE ratio of 27.52. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. Solventum has a twelve month low of $47.16 and a twelve month high of $85.92. The firm has a fifty day simple moving average of $73.42 and a 200 day simple moving average of $70.42.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the stock. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Solventum in the 4th quarter valued at $3,472,000. GF Fund Management CO. LTD. bought a new position in shares of Solventum during the fourth quarter valued at about $229,000. JT Stratford LLC boosted its holdings in Solventum by 17.5% during the fourth quarter. JT Stratford LLC now owns 26,692 shares of the company’s stock worth $1,763,000 after purchasing an additional 3,967 shares during the last quarter. Ananym Capital Management LP bought a new stake in Solventum in the 4th quarter worth about $17,620,000. Finally, Poehling Capital Management INC. increased its stake in Solventum by 271.2% in the 4th quarter. Poehling Capital Management INC. now owns 30,551 shares of the company’s stock valued at $2,018,000 after buying an additional 22,321 shares during the last quarter.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.